Open AccessEffectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
Author(s) -
Stefan Spittler,
Seibert,
Tracik,
Articus
Publication year - 2012
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s29116
Subject(s) - rivastigmine , medicine , tolerability , transdermal , disease , pharmacology , dementia , adverse effect , donepezil
Oral cholinesterase inhibitors at doses efficacious for the treatment of Alzheimer's disease (AD) are often prematurely discontinued due to gastrointestinal side effects. In controlled clinical trials, transdermal rivastigmine demonstrated less such effects at similar efficacy. The current study aimed to verify the validity of this data in daily practice.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom